Abstract：
BACKGROUND: Most patients with non-muscle invasive bladder cancer (NMIBC) have a high direction for recurrence and disease progression, which remains a significant unresolved challenge in bladder cancer patients. Therefore, a constant search is necessary for identifying appropriate and reliable biomarkers for early diagnosis of NMIBC. The current study has aimed to search for valuable diagnostic biomarkers in the tissue and urine specimens of NMIBC patients.
METHODS: The changes of twelve candidate mRNAs in a screening phase (40 tissue samples of NMIBC patients and their corresponding 40 urine specimens) and a subsequent independent validation phase (40 urine specimens) were estimated using real-time polymerase chain reaction (RT-qPCR). The receiver operating characteristic (ROC) analysis was executed to determine the potential diagnostic values of mRNAs.
RESULTS: The mRNA levels of seven candidate genes were markedly higher in tissue specimens relative to their neighboring tissues. Among them, four mRNAs, including ERBB2, CCND1, MKI67, and MAGEA6, were differentially expressed in urine samples of NMIBC patients relative to control subjects. Further, the expression of these four mRNAs was validated in the validation step. Combining these biomarkers showed better diagnostic performance than single biomarkers in the urine sample for non-invasive NMIBC detection. The combination of these mRNAs and cytology enhanced the sensitivity of cytology from 37% to 87%.
CONCLUSIONS: Our findings suggested that a four-mRNA panel may be promising in the non-invasive diagnosis of NMIBC, which deserves further investigation.
METHODS: The changes of twelve candidate mRNAs in a screening phase (40 tissue samples of NMIBC patients and their corresponding 40 urine specimens) and a subsequent independent validation phase (40 urine specimens) were estimated using real-time polymerase chain reaction (RT-qPCR). The receiver operating characteristic (ROC) analysis was executed to determine the potential diagnostic values of mRNAs.
RESULTS: The mRNA levels of seven candidate genes were markedly higher in tissue specimens relative to their neighboring tissues. Among them, four mRNAs, including ERBB2, CCND1, MKI67, and MAGEA6, were differentially expressed in urine samples of NMIBC patients relative to control subjects. Further, the expression of these four mRNAs was validated in the validation step. Combining these biomarkers showed better diagnostic performance than single biomarkers in the urine sample for non-invasive NMIBC detection. The combination of these mRNAs and cytology enhanced the sensitivity of cytology from 37% to 87%.
CONCLUSIONS: Our findings suggested that a four-mRNA panel may be promising in the non-invasive diagnosis of NMIBC, which deserves further investigation.
摘要：
背景：大多数非肌层浸润性膀胱癌（NMIBC）患者在复发和疾病进展方面具有很高的方向，这在膀胱癌患者中仍然是一个重大的未解决的挑战。因此,对于鉴定用于NMIBC早期诊断的合适且可靠的生物标志物,需要持续的搜索.当前的研究旨在在NMIBC患者的组织和尿液标本中寻找有价值的诊断生物标志物。
方法：使用实时聚合酶链反应（RT-qPCR）评估了12个候选mRNA在筛选阶段（40个NMIBC患者的组织样本及其相应的40个尿液样本）和随后的独立验证阶段（40个尿液样本）的变化。进行接受者操作特征(ROC)分析以确定mRNA的潜在诊断值。
结果：7个候选基因的mRNA水平在组织标本中相对于其邻近组织明显较高。其中,四个mRNA，包括ERBB2,CCND1,MKI67和MAGEA6在NMIBC患者的尿样中相对于对照组有差异表达.Further,在验证步骤中验证了这4种mRNA的表达.对于非侵入性NMIBC检测,组合这些生物标志物比尿液样品中的单一生物标志物显示出更好的诊断性能。这些mRNA和细胞学的组合将细胞学的敏感性从37%提高到87%。
结论：我们的研究结果表明，四mRNA小组在NMIBC的非侵入性诊断中可能是有希望的，这值得进一步调查。
方法：使用实时聚合酶链反应（RT-qPCR）评估了12个候选mRNA在筛选阶段（40个NMIBC患者的组织样本及其相应的40个尿液样本）和随后的独立验证阶段（40个尿液样本）的变化。进行接受者操作特征(ROC)分析以确定mRNA的潜在诊断值。
结果：7个候选基因的mRNA水平在组织标本中相对于其邻近组织明显较高。其中,四个mRNA，包括ERBB2,CCND1,MKI67和MAGEA6在NMIBC患者的尿样中相对于对照组有差异表达.Further,在验证步骤中验证了这4种mRNA的表达.对于非侵入性NMIBC检测,组合这些生物标志物比尿液样品中的单一生物标志物显示出更好的诊断性能。这些mRNA和细胞学的组合将细胞学的敏感性从37%提高到87%。
结论：我们的研究结果表明，四mRNA小组在NMIBC的非侵入性诊断中可能是有希望的，这值得进一步调查。
